IXICO plc New Contract with Biopharmaceutical Company (6359R)
September 25 2017 - 2:00AM
UK Regulatory
TIDMIXI
RNS Number : 6359R
IXICO plc
25 September 2017
25 September 2017
IXICO plc
("IXICO" or the "Company")
IXICO to provide specialist MR and PET imaging services in Phase
II Huntington's disease clinical trial
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today announces that it has signed a new contract
with a North American based biopharmaceutical company. The contract
value is GBP1.2m over a three year term.
IXICO will provide its technology enabled imaging services in a
Phase II clinical trial of a novel therapeutic to treat people with
Huntington's disease. As part of the study, IXICO will use its
TrialTracker(TM) digital platform and scientific services to
standardise the acquisition and collection of both MRI and PET
scans acquired at specialist imaging centres across North America.
This data will be analysed using IXICO's proprietary image analysis
workflows and algorithms to evaluate patient eligibility, monitor
patient safety and quantify drug effects.
Giulio Cerroni, Chief Executive of IXICO, said: "We are
delighted to continue our successful track record in Huntington's
disease clinical studies, providing compliant data standardisation,
collection and analysis to support regulatory submissions. This
first contract with a new customer also demonstrates the momentum
we are building with our commercially led growth strategy focused
on serving the needs of the biopharmaceutical industry".
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20
Officer 3763 7499
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield / 7408 4090
James Wolfe
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTOKQDNCBKKQCB
(END) Dow Jones Newswires
September 25, 2017 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2023 to Apr 2024